Makes a tiny titanium implant that surgeons thread into the eye's drainage canal to lower pressure in glaucoma patients.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- ScaleMarket cap is above the global median
Makes a tiny titanium implant that surgeons thread into the eye's drainage canal to lower pressure in glaucoma patients.
What this company is and how it runs — written from structure, not news.
Glaukos makes a sub-millimeter titanium stent that surgeons thread through the trabecular meshwork — the eye's primary drainage tissue — to permanently reduce the pressure that builds up in glaucoma. Because the stent opens a bypass channel measured in micrometers, manufacturing the device means holding tolerances so tight that a deviation acceptable in almost any other implant is enough to block the channel and cause the device to fail inside the eye. The clinical trials, FDA clearance, and Medicare reimbursement codes are all built specifically around that trabecular anatomy, so a surgeon trained on iStent's insertion technique, a hospital paid under those CPT codes, and a competitor seeking FDA clearance are each anchored to iStent's design — retraining, repricing, or rerouting through a different drainage site means rebuilding the evidence base from scratch. The single structural risk is that Medicare could cut or remove those procedure-specific reimbursement codes, which would make the economics of combined cataract-plus-stent surgery unworkable at the hospital level overnight, erasing the commercial infrastructure that years of accumulated clinical data built.
How does this company make money?
The company sells individual implants directly to hospitals and ambulatory surgery centers. Revenue is recognized when each device ships. There are no subscriptions or licensing fees — the company earns money one implant at a time, priced per procedure.
What makes this company hard to replace?
Surgeons trained on iStent's specific insertion technique through the trabecular meshwork would need to retrain for any alternative that targets a different drainage pathway — those are different anatomical skills. Hospital purchasing contracts negotiated through group purchasing organizations lock facilities into multi-year commitments. Any competing device targeting a different mechanism also has to build its own separate clinical evidence base, because the FDA labeling and efficacy data for trabecular micro-bypass does not transfer.
What limits this company?
The implant must be manufactured to tolerances measured in micrometers — a level of precision where even a tiny dimensional error is enough to block fluid flow inside the eye and cause the device to fail. Automated manufacturing can reduce cost at higher volumes, but it cannot loosen that tolerance. The anatomy of Schlemm's canal sets the precision requirement, and no process improvement can change that.
What does this company depend on?
The company cannot operate without FDA 510(k) clearance pathways for trabecular micro-bypass devices, reliable supply of biocompatible titanium alloy, specialized micro-manufacturing equipment capable of sub-millimeter precision, ophthalmology centers willing to run clinical trials, and Medicare reimbursement codes for MIGS procedures.
Who depends on this company?
Cataract surgeons who combine phacoemulsification with a MIGS procedure would lose their minimally invasive glaucoma treatment option during routine cataract surgery. Ambulatory surgery centers built around same-day eye procedures would lose revenue from simplified glaucoma interventions that avoid the complications of traditional trabeculectomy. Glaucoma patients with mild-to-moderate disease would be pushed toward more invasive filtering surgeries.
How does this company scale?
As unit volumes rise, manufacturing costs fall through automated micro-manufacturing and bulk titanium purchasing. What does not get cheaper or faster is surgeon adoption — each ophthalmologist needs hands-on repetitions with trabecular meshwork anatomy and MIGS technique before becoming comfortable, and no amount of capital investment speeds that up.
What external forces can significantly affect this company?
Medicare reimbursement rate changes to the CPT codes covering MIGS procedures directly affect whether hospitals choose to adopt the device at all. Aging populations in developed markets mean more people will develop glaucoma, but those same healthcare systems face budget pressure that makes device-based treatments harder to fund. Changes to FDA rules around 510(k) predicate device requirements could extend development timelines for next-generation versions of the implant.
Where is this company structurally vulnerable?
If Medicare eliminates or significantly cuts the CPT reimbursement codes that cover MIGS trabecular procedures, hospitals and ambulatory surgery centers would lose the financial justification for using the device. The price charged per implant is supported by what the procedure reimburses — not by the implant's value alone. Those billing codes exist because iStent built the category, so a reimbursement cut would dismantle the same commercial structure that took years of clinical evidence to construct.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph